MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results